Analysts Set iRadimed Corporation (NASDAQ:IRMD) PT at $120.00

iRadimed Corporation (NASDAQ:IRMD) has received a consensus rating of “Buy” from the five ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $120.00.

Several analysts have weighed in on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Lake Street Capital reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm reissued a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th.

iRadimed Price Performance

Shares of NASDAQ:IRMD opened at $95.56 on Tuesday. The business’s 50-day moving average is $99.41 and its 200 day moving average is $91.97. iRadimed has a 1 year low of $48.99 and a 1 year high of $107.90. The firm has a market capitalization of $1.22 billion, a P/E ratio of 54.61 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The business had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, analysts expect that iRadimed will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date was Monday, February 23rd. This is a boost from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio (DPR) is presently 45.71%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $100.04, for a total value of $500,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,250,000 shares in the company, valued at $225,090,000. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 45,000 shares of company stock valued at $4,482,950 over the last quarter. 36.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On iRadimed

Large investors have recently bought and sold shares of the company. CWM LLC increased its holdings in iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the period. Quarry LP purchased a new stake in shares of iRadimed in the 3rd quarter valued at $40,000. Farther Finance Advisors LLC boosted its holdings in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the period. Finally, State of Alaska Department of Revenue acquired a new stake in shares of iRadimed in the third quarter worth $47,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.